Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00526695|
Recruitment Status : Unknown
Verified July 2008 by University of Zurich.
Recruitment status was: Recruiting
First Posted : September 10, 2007
Last Update Posted : July 18, 2008
Sevoflurane preconditioning and cardiovascular protection against ischemia/reperfusion injury.
Study hypothesis: The volatile anesthetic sevoflurane at subanesthetic concentrations achieves endothelial protection against ischemia/reperfusion injury and reduces inflammatory markers in the circulation
|Condition or disease||Intervention/treatment||Phase|
|Ischemia/Reperfusion Injury||Drug: Sevoflurane (Preconditioning)||Phase 4|
Healthy volunteers are included in the study to investigate endothelial function and platelet activation after preconditioning by sevoflurane in subanesthetic concentrations.
Forearm perfusion, endothelial function and leukocyte/thrombocyte activation after tourniquet-induced ischemia/reperfusion injury of the forearm are measured using healthy volunteers in a cross-over design.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion, Leukocyte/Thrombocyte Activation, and Endothelial Function After Tourniquet-Induced Ischemia/Reperfusion Injury in the Forearm of Volunteers|
|Study Start Date :||January 2005|
|Estimated Primary Completion Date :||December 2008|
|Estimated Study Completion Date :||December 2008|
Drug: Sevoflurane (Preconditioning)
- marker expression on blood cells [ Time Frame: December 2008 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00526695
|Contact: 01 Studienregister MasterAdmins||+41 (0)44 255 11 11|
|University Hospital of Zurich||Recruiting|
|Contact: Michael Zaugg, MD email@example.com|
|Principal Investigator: Michael Zaugg, MD|
|Principal Investigator:||Michael Zaugg, PD Dr. med.||UniversitaetsSpital Zuerich|
|Principal Investigator:||Michael Zaugg, PD Dr. med.||University of Zurich|